What D&D Pharmatech does

D&D Pharmatech is a clinical-stage South Korean biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic, neurodegenerative, and fibrotic diseases. Its lead asset, DD01 (Zabopegdutide), is a GLP-1/glucagon dual-receptor agonist that demonstrated statistically significant Phase 2 48-week biopsy results in MASH at EASL 2026, with 81.8% of treated patients achieving ≥1-stage fibrosis improvement versus 18.8% on placebo. The pipeline also includes NLY01 (Pegsebrenatide), a GLP-1 receptor agonist in Phase 2 for progressive multiple sclerosis with Parkinson's and Alzheimer's in development, and TLY012, a first-in-class fibrosis treatment with FDA IND approval.

The company's technical differentiation rests on two proprietary platforms: ORALINK, an oral peptide formulation technology that enables tablet-form delivery of peptide drugs traditionally administered by injection, and Valted Seq (HiF-Seq™), an AI-driven big data platform for degenerative brain disease target discovery. D&D Pharmatech operates a US-dedicated clinical infrastructure through wholly-owned subsidiary Neuraly Inc., and holds a 15% stake in G-Alpha Therapeutics, a US affiliate developing alpha radiopharmaceutical cancer therapies using Astatine-211. Co-founders include Johns Hopkins researchers Ted M. Dawson, Valina L. Dawson, and Martin G. Pomper (inventor of the blockbuster PSMA PET imaging agent PYLARIFY).

As a pre-revenue clinical-stage company, D&D Pharmatech does not yet commercialize products and generates no product revenue. Its business model is structured around advancing its pipeline through clinical milestones to enable global out-licensing transactions with major pharmaceutical partners, supplemented by capital markets activity (KOSDAQ IPO in April 2024 and a 226.5 billion KRW convertible bond in April 2026) and strategic AI partnerships (LG AI Research). Future monetization is expected through upfront and milestone payments from licensing deals, with the company actively pursuing global technology out-licensing negotiations for DD01 following positive Phase 2 results.

Name

D&D Pharmatech

Legal name

(주)디앤디파마텍

Website

https://ddpharmatech.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

D&D Pharmatech is a South Korean clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for MASH, obesity, neurodegenerative diseases, and fibrosis, leveraging proprietary ORALINK oral peptide and AI-driven Valted Seq platforms, and monetizing through pipeline out-licensing to global pharma partners.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• GLP-1 therapeutics
• Metabolic disease drugs
• MASH treatment
• Peptide drug development
• Oral peptide formulations

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Distribution channels1 record

Marketing channels3 records

Core offering

D&D Pharmatech is a clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic diseases (MASH, obesity), neurodegenerative diseases (Parkinson's disease, multiple sclerosis), and fibrosis. Its pipeline includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist in Phase 2 for MASH; NLY01 (Pegsebrenatide) for neurodegenerative diseases; and TLY012, a first-in-class fibrosis treatment. The company leverages its proprietary ORALINK oral peptide formulation platform and AI-driven drug discovery partnerships.

Product overview

D&D Pharmatech is a South Korean biotech company specializing in GLP-1 peptide-based metabolic disease therapeutics. The core product portfolio includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist for MASH and obesity currently in Phase 2 trials available in oral and injectable forms; NLY01 (Pegsebrenatide) for progressive multiple sclerosis and Parkinson's disease in Phase 2; and TLY012, a first-in-class fibrosis treatment entering Phase 1. The company operates proprietary technology platforms including ORALINK for oral peptide delivery and Valted Sequencing (Valted Seq) for AI-driven target discovery in degenerative brain diseases. Through its U.S. subsidiary Neuraly, the company develops neurodegeneration treatments, while G-Alpha Therapeutics focuses on alpha radiopharmaceutical cancer therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• DD01 (Zabopegdutide) Dual GLP-1 and glucagon receptor agonist in Phase 2 clinical development for metabolic dysfunction-associated steatohepatitis (MASH), available in both oral and injectable formulations. The dual-receptor mechanism produces rapid liver fat reduction and has demonstrated statistically significant fibrosis improvement (81.8% achieving ≥1-stage fibrosis improvement vs 18.8% placebo) and MASH resolution at 48 weeks.
• NLY01 (Pegsebrenatide) GLP-1 receptor agonist in Phase 2 clinical trials for progressive multiple sclerosis, with additional development for Parkinson's disease and Alzheimer's disease. Targets a novel neuroprotective mechanism originally identified at Johns Hopkins University, with the program operated through U.S. subsidiary Neuraly Inc.
• TLY012 First-in-class fibrosis treatment targeting liver fibrosis with FDA IND approval, advancing into U.S. Phase 1/2 clinical development. Funded by the company's 2026 convertible bond issuance alongside the DD01 program.

Quantifiable outcome

• 81.8% of zabopegdutide-treated patients achieved >=1-stage fibrosis improvement vs 18.8% on placebo (p=0.001) at 48 weeks
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Altimmune: US clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for MASH and obesity in Phase 2b. Directly comparable mechanism to DD01 and competing for the same dual-agonist MASH positioning.
• Akero Therapeutics: US clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH in Phase 3 (SYNCHRONY program). Same indication (MASH) with strong histology data, competing for second-line MASH positioning behind Madrigal's Rezdiffra.
• Pliant Therapeutics: US clinical-stage biotech developing integrin-based therapies for fibrosis, including bexotegrast for idiopathic pulmonary fibrosis (Phase 2b/3). Directly comparable to D&D's TLY012 in fibrosis space with similar clinical-stage status and indication focus.
• Madrigal Pharmaceuticals: US biotech with first FDA-approved MASH drug Rezdiffra (resmetirom, a thyroid hormone receptor-beta agonist). Sets the benchmark for MASH commercial success and is the incumbent DD01 must displace or follow in clinical positioning.
• Viking Therapeutics: US clinical-stage biotech developing VK2735 (GLP-1/GIP dual agonist) for obesity and VK2809 for MASH. Highly relevant peer given adjacent incretin mechanism (GLP-1) and overlapping obesity/MASH indications.
• Terns Pharmaceuticals: US clinical-stage biotech focused on obesity and MASH with TERN-501 (THR-β agonist) and TERN-800 series (GLP-1). Same therapeutic areas as D&D with comparable clinical-stage positioning and partnership-driven strategy.
• Zealand Pharma: Denmark-based clinical-stage biotech co-developing survodutide, a GLP-1/glucagon dual agonist for MASH and obesity with Boehringer Ingelheim — the most directly competitive asset to D&D's DD01/Zabopegdutide due to identical mechanism and overlapping indications.

Broad incumbents

• Novo Nordisk: Global GLP-1 leader with Ozempic/Wegovy (semaglutide) for diabetes/obesity and pipeline MASH candidates. Sets the commercial benchmark for GLP-1 success and is the dominant force DD&D must compete against in obesity and potentially MASH.
• Eli Lilly: Global pharma with Mounjaro/Zepbound (tirzepatide, GLP-1/GIP) dominating obesity/diabetes. Major incumbent setting commercial dynamics and out-licensing benchmarks that any GLP-1 success — including DD01 — must be measured against.

Emerging players

• Keros Therapeutics: US clinical-stage biotech focused on TGF-beta family therapeutics for hematology and fibrosis (e.g., KER-050, KER-047). Comparable to D&D as a smaller clinical-stage biotech with fibrosis-adjacent pipeline and similar development-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ddpharmatech

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D&D Pharmatech